Renal Cell Carcinoma accounted for a 2.5% share of the global clinical trials within the Oncology therapy area in 2020, registering an increase of 0.2% when compared with the last ten-year average of 2.3% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Renal Cell Carcinoma
Industry sponsored trials held a 58.3% share of all the clinical trials for Renal Cell Carcinoma indication in 2020, registering an increase of 9.5% when compared with the ten-year average of 48.8%. Non-industry sponsored trials accounted for a 41.7% share in 2020, marking a decrease of 9.5% over the ten-year average of 51.2%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Renal Cell Carcinoma trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Renal Cell Carcinoma trials, accounting for a 50.7% share in 2020, when compared with the five-year average of 46.2% and ten-year average of 41.7%.
Europe was at the second position with a 39.4% share in 2020, over the five-year average of 42.1% and ten-year average of 43.8%, followed by North America with a 39.4% share in 2020, as against five-year and ten-year averages of 63.8% and 66.0% respectively.
Middle East and Africa stood fourth with an 8.5% share in 2020, compared with the five-year average of 5.6% and ten-year average of 5.3%, followed by South and Central America with a 4.2% share in 2020, over five-year and ten-year averages of 6.4% and 7.3% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Renal Cell Carcinoma trials, accounting for a 38.0% share in 2020, as against the five-year average of 61.9% and ten-year average of 64.2%.
Russia held a 21.1% share in 2020, over the five-year average of 10.9% and ten-year average of 9.8%, followed by China with an 18.3% share in 2020, compared with the five-year and ten-year averages of 15.0% and 12.1% respectively.
Canada held a 14.1% share in 2020, as against the five-year average of 16.3% and ten-year average of 18.5%.
Australia held a 14.1% share in 2020, over the five-year and ten-year averages of 19.6% and 14.6% respectively.
Top regions of non-industry sponsored Renal Cell Carcinoma trials
North America was the top region for non-industry sponsored Renal Cell Carcinoma trials, accounting for a 53.1% share in 2020 when compared with the five-year average of 48.7% and ten-year average of 44.8%.
Asia-Pacific was at the second position with a 28.6% share in 2020, over the five-year and ten-year averages of 22.8% and 26.9% respectively, followed by Europe with an 18.4% share in 2020, as against the five-year average of 27.6% and ten-year average of 28.0%.
Middle East and Africa stood at the fourth position with a 2.0% share in 2020, compared with the five-year average of 0.3% and ten-year average of 0.5%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 1.2% and 0.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for non-industry sponsored Renal Cell Carcinoma trials, accounting for a 49.0% share in 2020, as against the five-year average of 48.0% and ten-year average of 42.3%.
China held a 20.4% share in 2020, over the five-year average of 9.2% and ten-year average of 7.5%, followed by Denmark with a 6.1% share, compared with the five-year and ten-year averages of 0.7% and 0.5% respectively.
Canada held a 4.1% share in 2020, as against the five-year average of 1.9% and ten-year average of 3.7%.
Italy held a 4.1% share in 2020, over the five-year average of 7.5% and ten-year average of 6.3%.
Phase I trials lead industry sponsored clinical trials for Renal Cell Carcinoma in 2020
Phase I trials held a 55.8% share of industry sponsored clinical trials for Renal Cell Carcinoma in 2020, over the five-year average of 47.8% and ten-year average of 43.9%.
Phase II trials held a 29.9% share in 2020, as against the five-year average of 33.9% and ten-year average of 34.0%. Phase IV trials held a 7.8% share in 2020, compared with the five-year and ten-year averages of 9.7% and 13.9% respectively.
Phase III trials held a 6.5% share in 2020, over the five-year average of 8.5% and ten-year average of 8.2%.
Phase II trials lead non-industry sponsored clinical trials for Renal Cell Carcinoma in 2020
Phase II trials held a 54.5% share of non-industry sponsored clinical trials for Renal Cell Carcinoma in 2020, over the five-year average of 66.9% and ten-year average of 66.9%.
Phase I trials held a 20.0% share in 2020, as against the five-year average of 20.2% and ten-year average of 19.0%. Phase III trials held a 14.5% share, compared with the five-year and ten-year averages of 2.8% and 3.7% respectively.
Phase IV trials held a 10.9% share in 2020, over the five-year average of 10.1% and ten-year average of 10.4%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
